Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Rejoni, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Rejoni, Inc.

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Rejoni, Inc.. It includes 1 original PMA approval. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 28, 2026 to Oct 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MCN appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250051, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 201 Burlington Rd., North Bldg., Second Floor, Bedford, MA, 01730. Recorded on P250051/S001, decision dated Oct 28, 2026.

Changes described in PMA records

P250051/S001: Juveena Hydrogel System

The FDA database records a 30-Day Notice for the Juveena Hydrogel System, submitted by Rejoni, Inc. The stated purpose is a change to remove visible particulates prior to final packaging. The supplement type is a Process Change involving the Manufacturer/Sterilizer/Packager/Supplier, and the decision is recorded as OK30.

This notice is not a new approval of the whole system and does not establish safety or clinical effectiveness. The device is classified as a barrier, absorbable, adhesion product under product code MCN in Obstetrics/Gynecology. The source statement does not specify the particulate removal method, the manufacturing stage affected, or any resulting performance data.

FDA approval-order wording

a change to remove visible particulates prior to final packaging

Oct 28, 2026 · 30-Day Notice

P250051: Juveena Hydrogel System

The FDA approved the Juveena Hydrogel System from Rejoni, Inc. on September 28, 2026. The approval covers use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.

The approval also includes the Rejoni Acorn Catheter, which is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity. The device is classified as an absorbable adhesion barrier under product code MCN in obstetrics and gynecology. The database record does not include supplement type or supplement reason fields.

FDA approval-order wording

Approval for Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.The Rejoni Acorn Catheter is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity.

Sep 28, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Rejoni, Inc.PMA supplementOct 28, 2026FDA
Rejoni, Inc.PMA approvalSep 28, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.